In this article, we present data on a critical role of OATP1B transporters to liver physiology. Although we had recently shown the importance of OATP1B transporters to hepatic drug disposition using Slco1b2−/− mice,7 the role of this transporter Talazoparib clinical trial to liver-specific glucose and cholesterol metabolism through modulation of TR signaling pathways, particularly with its remarkable effect on hepatic GLUT2 expression, was completely unexpected. Indeed, we would have predicted that because several OATP transporters have been shown to be capable of mediating cellular uptake of THs,1 absence of a single

isoform would not affect hepatic physiology in such a way. However, the role of transport in TH activity is supported by findings in the central nervous system, where mutations in MCT-8 (SLC16A2) have been shown to result in mental retardation due to reduced neuronal TH entry.19, 20 It is remarkable that despite the multiplicity of transporters expressed in liver capable of TH transport, OATP1B transporters appear to have a dominant role in controlling hepatic hormone status both in mice and in humans. It should be noted that a recent Selleck Osimertinib study by van der Deure et al.21 suggested that OATP1B1 can also transport TH metabolites such as iodothyronine

sulphates (T4S) and that T4S plasma levels are different in individuals harboring the SLCO1B1 c.521C>T polymorphism, but the SNP was not associated with statistically significant changes to parent TH levels. However, their data show that the level

of fT4 at least in healthy volunteers appeared slightly higher in individuals harboring the polymorphism (521CC versus 521CT/TT, 14.8 ± 0.2 versus 15.6 ± 0.3; P = 0.06). In accordance with those C-X-C chemokine receptor type 7 (CXCR-7) findings, we show that absence of Oatp1b2 manifests as altered hepatocellular response to THs, whereas plasma levels of fT3 and TSH are unchanged and the levels of fT4 are slightly but significantly higher in knockout mice. Biological activity of THs is partly controlled by conversion of circulating T4 to the more active T3 catalyzed by intracellular iodothyronine 5′-deiodinases. In nonhepatic tissues 5′-deiodinase type 2 (DIO2), catalyzes the conversion of T4 to T3 and therefore controls the cellular activity, whereas DIO1 catalyzes the conversion of T4 to equimolar amounts of T3 and the biologically inactive reverse T3 and thereby modulates the plasma levels of T3.22-24 Linking Oatp1b2 to hepatic TH function was clearly supported by our observation that expression of the widely studied and well-defined TR target gene, Dio1, a sensitive marker of hepatic TH status,25, 26 was markedly reduced in livers of Slco1b2−/− mice. Biological activity of THs arises from activation of intracellular nuclear hormone receptors.27 TRβ is the predominant TR in the liver and is thought to mediate the cholesterol-lowering effects of TH therapy.